Absorica Ld is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 2 US drug patents filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 04, 2035. Details of Absorica Ld's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9700535 | Oral pharmaceutical composition of isotretinoin |
Aug, 2035
(10 years from now) | Active |
| US9750711 | Low dose oral pharmaceutical composition of isotretinoin |
May, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Absorica Ld's patents.
Latest Legal Activities on Absorica Ld's Patents
Given below is the list of recent legal activities going on the following patents of Absorica Ld.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Mar, 2021 | US9750711 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2021 | US9700535 |
| Email Notification Critical | 31 Oct, 2018 | US9700535 |
| Email Notification Critical | 31 Oct, 2018 | US9750711 |
| Change in Power of Attorney (May Include Associate POA) Critical | 31 Oct, 2018 | US9750711 |
| Change in Power of Attorney (May Include Associate POA) Critical | 31 Oct, 2018 | US9700535 |
| Correspondence Address Change Critical | 30 Oct, 2018 | US9750711 |
| Correspondence Address Change Critical | 30 Oct, 2018 | US9700535 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Sep, 2017 | US9750711 |
| Recordation of Patent Grant Mailed Critical | 05 Sep, 2017 | US9750711 |
US patents provide insights into the exclusivity only within the United States, but Absorica Ld is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Absorica Ld's family patents as well as insights into ongoing legal events on those patents.
Absorica Ld's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Absorica Ld's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 04, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Absorica Ld Generic API suppliers:
Isotretinoin is the generic name for the brand Absorica Ld. 9 different companies have already filed for the generic of Absorica Ld, with Upsher Smith Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Absorica Ld's generic
Alternative Brands for Absorica Ld
There are several other brand drugs using the same active ingredient (Isotretinoin) as Absorica Ld. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Sun Pharm Inds Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Isotretinoin, Absorica Ld's active ingredient. Check the complete list of approved generic manufacturers for Absorica Ld
About Absorica Ld
Absorica Ld is a drug owned by Sun Pharmaceutical Industries Ltd. Absorica Ld uses Isotretinoin as an active ingredient. Absorica Ld was launched by Sun Pharm in 2019.
Approval Date:
Absorica Ld was approved by FDA for market use on 05 November, 2019.
Active Ingredient:
Absorica Ld uses Isotretinoin as the active ingredient. Check out other Drugs and Companies using Isotretinoin ingredient
Dosage:
Absorica Ld is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 24MG | CAPSULE | Prescription | ORAL |
| 8MG | CAPSULE | Prescription | ORAL |
| 32MG | CAPSULE | Prescription | ORAL |
| 28MG | CAPSULE | Discontinued | ORAL |
| 16MG | CAPSULE | Prescription | ORAL |
| 20MG | CAPSULE | Discontinued | ORAL |